CN114703212B - Method for modifying laccase by using specific segment random mutation method and laccase strain LAC123 - Google Patents
Method for modifying laccase by using specific segment random mutation method and laccase strain LAC123 Download PDFInfo
- Publication number
- CN114703212B CN114703212B CN202210194874.XA CN202210194874A CN114703212B CN 114703212 B CN114703212 B CN 114703212B CN 202210194874 A CN202210194874 A CN 202210194874A CN 114703212 B CN114703212 B CN 114703212B
- Authority
- CN
- China
- Prior art keywords
- laccase
- sequence
- random mutation
- random
- lac123
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010029541 Laccase Proteins 0.000 title claims abstract description 46
- 230000035772 mutation Effects 0.000 title abstract description 51
- 238000000034 method Methods 0.000 title abstract description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 abstract description 40
- 102000004190 Enzymes Human genes 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 20
- 108020004414 DNA Proteins 0.000 abstract description 19
- 238000002744 homologous recombination Methods 0.000 abstract description 15
- 230000006801 homologous recombination Effects 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 238000012216 screening Methods 0.000 abstract description 10
- 238000012163 sequencing technique Methods 0.000 abstract description 10
- 241000588724 Escherichia coli Species 0.000 abstract description 9
- 239000012634 fragment Substances 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 101000946191 Galerina sp Laccase-1 Proteins 0.000 abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 6
- 238000004458 analytical method Methods 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 12
- 239000013598 vector Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 101150075844 LAC1 gene Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- SUEIIIFUBHDCCS-PBCZWWQYSA-N Asn-His-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SUEIIIFUBHDCCS-PBCZWWQYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 238000007852 inverse PCR Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 108010024607 phenylalanylalanine Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- FXKNPWNXPQZLES-ZLUOBGJFSA-N Ala-Asn-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FXKNPWNXPQZLES-ZLUOBGJFSA-N 0.000 description 1
- KMGOBAQSCKTBGD-DLOVCJGASA-N Ala-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CN=CN1 KMGOBAQSCKTBGD-DLOVCJGASA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 1
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 1
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
- PDQBXRSOSCTGKY-ACZMJKKPSA-N Asn-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PDQBXRSOSCTGKY-ACZMJKKPSA-N 0.000 description 1
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 1
- QGNXYDHVERJIAY-ACZMJKKPSA-N Asn-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N QGNXYDHVERJIAY-ACZMJKKPSA-N 0.000 description 1
- VITDJIPIJZAVGC-VEVYYDQMSA-N Asn-Met-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VITDJIPIJZAVGC-VEVYYDQMSA-N 0.000 description 1
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 1
- VHQSGALUSWIYOD-QXEWZRGKSA-N Asn-Pro-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O VHQSGALUSWIYOD-QXEWZRGKSA-N 0.000 description 1
- XTMZYFMTYJNABC-ZLUOBGJFSA-N Asn-Ser-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N XTMZYFMTYJNABC-ZLUOBGJFSA-N 0.000 description 1
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 1
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 1
- CGYKCTPUGXFPMG-IHPCNDPISA-N Asn-Tyr-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O CGYKCTPUGXFPMG-IHPCNDPISA-N 0.000 description 1
- ZSVJVIOVABDTTL-YUMQZZPRSA-N Asp-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N ZSVJVIOVABDTTL-YUMQZZPRSA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 1
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 1
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 1
- KRQFMDNIUOVRIF-KKUMJFAQSA-N Asp-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC(=O)O)N KRQFMDNIUOVRIF-KKUMJFAQSA-N 0.000 description 1
- HJZLUGQGJWXJCJ-CIUDSAMLSA-N Asp-Pro-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJZLUGQGJWXJCJ-CIUDSAMLSA-N 0.000 description 1
- QTIZKMMLNUMHHU-DCAQKATOSA-N Asp-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QTIZKMMLNUMHHU-DCAQKATOSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- ZUNMTUPRQMWMHX-LSJOCFKGSA-N Asp-Val-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O ZUNMTUPRQMWMHX-LSJOCFKGSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- BIVLWXQGXJLGKG-BIIVOSGPSA-N Cys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N)C(=O)O BIVLWXQGXJLGKG-BIIVOSGPSA-N 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 1
- LLRJEFPKIIBGJP-DCAQKATOSA-N Gln-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N LLRJEFPKIIBGJP-DCAQKATOSA-N 0.000 description 1
- MWERYIXRDZDXOA-QEWYBTABSA-N Gln-Ile-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MWERYIXRDZDXOA-QEWYBTABSA-N 0.000 description 1
- VZRAXPGTUNDIDK-GUBZILKMSA-N Gln-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N VZRAXPGTUNDIDK-GUBZILKMSA-N 0.000 description 1
- YLABFXCRQQMMHS-AVGNSLFASA-N Gln-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O YLABFXCRQQMMHS-AVGNSLFASA-N 0.000 description 1
- VYOILACOFPPNQH-UMNHJUIQSA-N Gln-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N VYOILACOFPPNQH-UMNHJUIQSA-N 0.000 description 1
- SWDNPSMMEWRNOH-HJGDQZAQSA-N Glu-Pro-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWDNPSMMEWRNOH-HJGDQZAQSA-N 0.000 description 1
- FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 1
- LLXVQPKEQQCISF-YUMQZZPRSA-N Gly-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN LLXVQPKEQQCISF-YUMQZZPRSA-N 0.000 description 1
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- WZSHYFGOLPXPLL-RYUDHWBXSA-N Gly-Phe-Glu Chemical compound NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O WZSHYFGOLPXPLL-RYUDHWBXSA-N 0.000 description 1
- FEUPVVCGQLNXNP-IRXDYDNUSA-N Gly-Phe-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FEUPVVCGQLNXNP-IRXDYDNUSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- LMMPTUVWHCFTOT-GARJFASQSA-N His-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O LMMPTUVWHCFTOT-GARJFASQSA-N 0.000 description 1
- AASLOGQZZKZWKH-SRVKXCTJSA-N His-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N AASLOGQZZKZWKH-SRVKXCTJSA-N 0.000 description 1
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 description 1
- OQDLKDUVMTUPPG-AVGNSLFASA-N His-Leu-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OQDLKDUVMTUPPG-AVGNSLFASA-N 0.000 description 1
- VCBWXASUBZIFLQ-IHRRRGAJSA-N His-Pro-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O VCBWXASUBZIFLQ-IHRRRGAJSA-N 0.000 description 1
- DGLAHESNTJWGDO-SRVKXCTJSA-N His-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N DGLAHESNTJWGDO-SRVKXCTJSA-N 0.000 description 1
- XSEAJSPAOTZXJE-IHPCNDPISA-N His-Trp-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)N XSEAJSPAOTZXJE-IHPCNDPISA-N 0.000 description 1
- GGXUJBKENKVYNV-ULQDDVLXSA-N His-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N GGXUJBKENKVYNV-ULQDDVLXSA-N 0.000 description 1
- TZCGZYWNIDZZMR-NAKRPEOUSA-N Ile-Arg-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)O)N TZCGZYWNIDZZMR-NAKRPEOUSA-N 0.000 description 1
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 1
- VZIFYHYNQDIPLI-HJWJTTGWSA-N Ile-Arg-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N VZIFYHYNQDIPLI-HJWJTTGWSA-N 0.000 description 1
- HGNUKGZQASSBKQ-PCBIJLKTSA-N Ile-Asp-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HGNUKGZQASSBKQ-PCBIJLKTSA-N 0.000 description 1
- UBHUJPVCJHPSEU-GRLWGSQLSA-N Ile-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N UBHUJPVCJHPSEU-GRLWGSQLSA-N 0.000 description 1
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 1
- PKGGWLOLRLOPGK-XUXIUFHCSA-N Ile-Leu-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PKGGWLOLRLOPGK-XUXIUFHCSA-N 0.000 description 1
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 1
- UYNXBNHVWFNVIN-HJWJTTGWSA-N Ile-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=CC=C1 UYNXBNHVWFNVIN-HJWJTTGWSA-N 0.000 description 1
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- MDVZJYGNAGLPGJ-KKUMJFAQSA-N Leu-Asn-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MDVZJYGNAGLPGJ-KKUMJFAQSA-N 0.000 description 1
- HUEBCHPSXSQUGN-GARJFASQSA-N Leu-Cys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N HUEBCHPSXSQUGN-GARJFASQSA-N 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- VULJUQZPSOASBZ-SRVKXCTJSA-N Leu-Pro-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O VULJUQZPSOASBZ-SRVKXCTJSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- CRIODIGWCUPXKU-AVGNSLFASA-N Lys-Pro-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(O)=O CRIODIGWCUPXKU-AVGNSLFASA-N 0.000 description 1
- ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 description 1
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 1
- KYXDADPHSNFWQX-VEVYYDQMSA-N Met-Thr-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O KYXDADPHSNFWQX-VEVYYDQMSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 101100234831 Oryza sativa subsp. japonica LAC23 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- AGYXCMYVTBYGCT-ULQDDVLXSA-N Phe-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O AGYXCMYVTBYGCT-ULQDDVLXSA-N 0.000 description 1
- HHOOEUSPFGPZFP-QWRGUYRKSA-N Phe-Asn-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HHOOEUSPFGPZFP-QWRGUYRKSA-N 0.000 description 1
- WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 1
- KNYPNEYICHHLQL-ACRUOGEOSA-N Phe-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 KNYPNEYICHHLQL-ACRUOGEOSA-N 0.000 description 1
- JXQVYPWVGUOIDV-MXAVVETBSA-N Phe-Ser-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JXQVYPWVGUOIDV-MXAVVETBSA-N 0.000 description 1
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 1
- JTKGCYOOJLUETJ-ULQDDVLXSA-N Phe-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JTKGCYOOJLUETJ-ULQDDVLXSA-N 0.000 description 1
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- UTAUEDINXUMHLG-FXQIFTODSA-N Pro-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 UTAUEDINXUMHLG-FXQIFTODSA-N 0.000 description 1
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 1
- ULIWFCCJIOEHMU-BQBZGAKWSA-N Pro-Gly-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 ULIWFCCJIOEHMU-BQBZGAKWSA-N 0.000 description 1
- AQSMZTIEJMZQEC-DCAQKATOSA-N Pro-His-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)O AQSMZTIEJMZQEC-DCAQKATOSA-N 0.000 description 1
- IBGCFJDLCYTKPW-NAKRPEOUSA-N Pro-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 IBGCFJDLCYTKPW-NAKRPEOUSA-N 0.000 description 1
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 1
- GNADVDLLGVSXLS-ULQDDVLXSA-N Pro-Phe-His Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O GNADVDLLGVSXLS-ULQDDVLXSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- OOZJHTXCLJUODH-QXEWZRGKSA-N Pro-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 OOZJHTXCLJUODH-QXEWZRGKSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010079005 RDV peptide Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- SFZKGGOGCNQPJY-CIUDSAMLSA-N Ser-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N SFZKGGOGCNQPJY-CIUDSAMLSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- JBHMLZSKIXMVFS-XVSYOHENSA-N Thr-Asn-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JBHMLZSKIXMVFS-XVSYOHENSA-N 0.000 description 1
- VBPDMBAFBRDZSK-HOUAVDHOSA-N Thr-Asn-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VBPDMBAFBRDZSK-HOUAVDHOSA-N 0.000 description 1
- VYEHBMMAJFVTOI-JHEQGTHGSA-N Thr-Gly-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O VYEHBMMAJFVTOI-JHEQGTHGSA-N 0.000 description 1
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- SIEZEMFJLYRUMK-YTWAJWBKSA-N Thr-Met-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N)O SIEZEMFJLYRUMK-YTWAJWBKSA-N 0.000 description 1
- NQQMWWVVGIXUOX-SVSWQMSJSA-N Thr-Ser-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NQQMWWVVGIXUOX-SVSWQMSJSA-N 0.000 description 1
- SJPDTIQHLBQPFO-VLCNGCBASA-N Thr-Tyr-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SJPDTIQHLBQPFO-VLCNGCBASA-N 0.000 description 1
- KPMIQCXJDVKWKO-IFFSRLJSSA-N Thr-Val-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPMIQCXJDVKWKO-IFFSRLJSSA-N 0.000 description 1
- ILUOMMDDGREELW-OSUNSFLBSA-N Thr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O ILUOMMDDGREELW-OSUNSFLBSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- CZWIHKFGHICAJX-BPUTZDHNSA-N Trp-Glu-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 CZWIHKFGHICAJX-BPUTZDHNSA-N 0.000 description 1
- PWPJLBWYRTVYQS-PMVMPFDFSA-N Trp-Phe-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PWPJLBWYRTVYQS-PMVMPFDFSA-N 0.000 description 1
- NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 description 1
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 1
- VTCKHZJKWQENKX-KBPBESRZSA-N Tyr-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O VTCKHZJKWQENKX-KBPBESRZSA-N 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- COSLEEOIYRPTHD-YDHLFZDLSA-N Val-Asp-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 COSLEEOIYRPTHD-YDHLFZDLSA-N 0.000 description 1
- NXRAUQGGHPCJIB-RCOVLWMOSA-N Val-Gly-Asn Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O NXRAUQGGHPCJIB-RCOVLWMOSA-N 0.000 description 1
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 1
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 1
- YKZVPMUGEJXEOR-JYJNAYRXSA-N Val-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N YKZVPMUGEJXEOR-JYJNAYRXSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 108010089198 phenylalanyl-prolyl-arginine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 108010007513 prolyl-glycyl-prolyl-leucine Proteins 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0061—Laccase (1.10.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03002—Laccase (1.10.3.2)
Abstract
The invention discloses a method for modifying laccase by using a specific segment random mutation method and a laccase strain lac123. According to the invention, through analysis, an important functional section, which is close to laccase active sites, of a second structural domain and a third structural domain of LAC1 is selected as a target sequence, when DNA of the sequence is chemically synthesized, a degenerate primer method is adopted to introduce random mutation at specific base sites, the synthesized random fragment is replaced by a homologous recombination method, the same fragment of wild enzyme is replaced, a random mutation library containing DNA sequences of specific sites of the specific sections is constructed, library capacity is detected through second generation sequencing, and batch screening of laccase activity is carried out on E.coli clones in the random mutation library, 5 laccase with improved enzyme activity is obtained through initial screening, and a mutant laccase strain LAC123 with 2.3 times of improved enzyme activity is obtained through shake flask rescreening, and the expressed protein sequence is shown as SEQ ID NO. 3.
Description
Technical Field
The invention relates to a method for modifying laccase by using a specific segment random mutation method and a laccase strain LAC123, belonging to the technical fields of molecular biology and enzyme engineering.
Background
Laccase (EC 1.10.3.2) is a biocatalyst capable of reducing oxygen into water without producing harmful byproducts, has very wide action substrates, is considered as an enzyme of environment-friendly, is greatly concerned in the fields of environment, industry and biotechnology at present, but the existing laccase has the defects of low enzyme activity, poor thermal stability and the like, and has special reaction systems such as high temperature, strong acid, strong base, high salt, toxic medium and the like in industrial production, the traditional wild laccase is extremely easy to inactivate, and the production requirements cannot be met. Molecular transformation is used as an important means for improving the enzyme yield and the enzyme properties, and is widely applied increasingly, so that great economic benefit and profound scientific significance are brought.
Enzyme molecular engineering is a technology for obtaining a novel enzyme which is hoped by people and not found in nature by directionally engineering enzyme molecules aiming at the defects of the enzyme in the nature. Along with the deep understanding of enzymes, through analyzing the information such as enzyme gene sequences, spatial structures, catalytic modes and the like, the ideas and means for modifying enzyme molecules are more and more combined with advanced molecular biology means. The current methods applicable to modification of enzyme molecules are mainly divided into two methods, namely a chemical modification method and a biological enzyme engineering method. The chemical modification of the enzyme changes the catalytic property of the enzyme by attaching or removing some chemical groups on the side chain groups of the enzyme, and the method is simpler, but is easy to change the physicochemical property. The ideal mode is to adjust the amino acid of the key part of the enzyme molecule so as to generate a satisfactory effect, and along with the development of genetic engineering technology and proteomics, people can analyze the amino acid sequence and the protein structure of the enzyme, manually simulate the enzyme by using a bioinformatics method, and design and reform the enzyme based on the existing laccase sequence so as to have expected excellent performance, thereby achieving the aim of better and wider utilization.
The current methods for introducing mutation into protein genes include site-directed mutagenesis, error-prone PCR, DNA rearrangement, N-terminal fusion signal peptide and the like, and although specific operation methods are different, the design concept is to construct a mutation library based on the DNA sequence of the existing enzyme, and then select mutants with specific properties by using a proper batch screening method, so as to finally obtain the enzyme with more excellent properties in certain aspects.
Searching domestic and foreign documents and patents, no related report of a technology for constructing a mutation library by connecting random mutation sequences through homologous recombination is found at present.
Disclosure of Invention
The technical problems to be solved by the invention are as follows: how to obtain laccase with higher enzyme activity by a specific segment random mutation method.
In order to solve the technical problems, the invention provides a method for modifying laccase by using a specific segment random mutation method, which comprises the following steps:
step 1: extracting a DNA sequence of a white rot fungus laccase LAC1 gene, comparing the DNA sequence with laccase domains and active center sequences in a database, and selecting important functional sections, close to laccase active sites, of a second domain and a third domain of LAC1 as target sequences;
step 2: when the target sequence is chemically synthesized, introducing random mutation into a specific plurality of base sites by adopting a degenerate primer method to obtain a random mutation sequence;
step 3: synthesizing a DNA fragment of a random mutation sequence, obtaining a pET-32a (+) -LAC1 vector with a target sequence removed from a LAC1 gene sequence in an inverse PCR mode, connecting the DNA fragment of the random mutation sequence with the vector pET-32a (+) -LAC1 through a homologous recombination reaction, and transferring the DNA fragment into escherichia coli DH5 alpha to obtain a LAC1 mutation library;
step 4: combining bacterial colonies in the mutant library to extract plasmids, using the plasmids for second-generation sequencing library construction and transferring the plasmids into E.coli BL21 (DE 3) cells for activity screening, and screening by a 96-well plate high-throughput fungus shaking method to obtain laccase strains with improved enzyme activity.
Preferably, the random mutation sequence in step 2 comprises a sequence as set forth in SEQ ID NO:1 and SEQ ID NO:2, a sequence shown in seq id no; the SEQ ID NO:1 and SEQ ID NO:2, wherein N is A, T, C or G.
Preferably, in the step 3, the sequence shown in SEQ ID NO:1 comprises the following forward sequence and reverse sequence:
forward sequence: CACTCCTTCCTCTACGACTT;
reverse sequence: CGCAGGCCGTCACAGTACTGGG.
Preferably, in the step 3, the sequence shown in SEQ ID NO:2 comprises the following forward sequence and reverse sequence:
forward sequence: TTCGCCATCGTCTTCGCCGA;
reverse sequence: GCAGCTTGTCGTAGATGGGA.
Preferably, the substrate for the homologous recombination reaction in step 3 comprises:
140ng of carrier;
20ng of DNA fragment of random mutation sequence;
2×ClonExpress Mix 5μL;
ddH 2 o was filled to 10. Mu.L;
the homologous recombination reaction is carried out by the following steps: the reaction was carried out at 50℃for 15min.
The invention also provides a laccase strain LAC123 with improved enzyme activity, which is obtained by the method for reforming laccase by using the random mutation method of the specific section, wherein the laccase strain LAC123 contains an expression protein with an amino acid sequence shown as SEQ ID NO. 3.
Compared with the prior art, the invention has the beneficial effects that:
1. the method for modifying laccase by using specific segment random mutation method has convenient operation, strong mutation purpose, 1 mutation site or n mutation sites, random base doping, random mutation library capacity up to 4n in principle, recombination of A and T, G, C to form codon diversity, strong pertinence and high beneficial mutation rate, can be successfully applied to various performance screening, such as improving protease activity, enhancing protein stability, changing protein to substrate specificity selection, protein enantioselectivity, enhancing protein solubility and protein affinity, and the like, and has wide application;
2. the method provided by the invention screens and obtains a strain with 2.3 times of enzyme activity improved than that of wild laccase, and has a good application prospect in industry.
Drawings
FIG. 1 is a schematic diagram of the construction of a random mutant sequence recombinant vector pET-32a (+) -LAC 1;
FIG. 2 is a schematic representation of a homologous recombination linked random mutant sequence;
FIG. 3 is a schematic representation of the visual analysis of random mutant sequence 1 by IGV;
FIG. 4 is a schematic representation of IGV visual analysis of random mutant sequence 2;
FIG. 5 is a diagram showing an alignment of the LAC123 and LAC1 modified laccase strains;
FIG. 6 is a three-dimensional structural model of an engineered laccase LAC123.
Detailed Description
In order to make the invention more comprehensible, preferred embodiments accompanied with figures are described in detail below.
The invention compares the DNA sequence (SEQ ID NO: 4) of white rot fungus laccase LAC1 gene with laccase structural domain and active center sequence in database, selects important functional sections near laccase active site of LAC1 second structural domain and third structural domain as target sequence, adopts degenerate primer method to introduce random mutation at specific several base sites when synthesizing the sequence DNA, replaces the same segment of wild enzyme by homologous recombination method, constructs random mutation library containing specific section specific site DNA sequence, detects library capacity by second generation sequencing, performs batch screening of laccase activity on E.coli clone in random mutation library, screens to obtain 5 strains with obviously improved enzyme activity, and performs shake flask re-screening to obtain mutant laccase with 2.3 times of enzyme activity improvement.
The invention designs a DNA segment containing upstream and downstream sequences aiming at a DNA segment needing to introduce random mutation at a plurality of bases, wherein the length is about 50 bases, when the DNA segment is chemically synthesized, the random bases are introduced at the target sites through a degenerate primer synthesis method, the upstream and downstream primers containing homologous arms are designed, the DNA segment is subjected to PCR amplification, a pET-32a (+) -LAC1 vector with the segment removed from the LAC1 gene sequence is obtained through an inverse PCR method, the random mutation sequence is constructed into the vector through a homologous recombination method by the mutation segment and the vector segment, and is transferred into E.coli DH5 alpha to obtain a LAC1 mutation library, colonies in the mutation library are combined to extract plasmids for secondary sequencing and library construction and transfer into E.coli BL21 (DE 3) cells for activity screening.
According to the invention, with reference to 96-well plate high-throughput shaking bacteria of Ouyang Fengju et al, BL21 (DE 3) transformation plate clones are respectively inoculated into 96-well plates into which 150 mu L of LB medium containing Amp has been previously added into each well, and placed in a constant temperature incubator at 37 ℃ overnight. The rear holes are sucked 20Mu L of bacterial liquid cultured overnight is transferred into another pore plate containing 130 mu L of liquid culture medium for culturing for 2-3 hours until OD600 reaches about 0.6-0.8, 2 mu L of 100 mu M IPTG is added into each pore, induced expression is carried out at 16 ℃, and the bacterial liquid is collected by centrifugation of 96 pore plates every other day, and the culture medium is poured out. And adding lysozyme into each hole to lyse cells, repeatedly blowing by using a gun head to form uniform suspension, centrifuging and collecting supernatant. Another 96-well plate was prepared, 50. Mu. LpH 4.0.0 disodium hydrogen phosphate-citric acid buffer was added to each well, incubated in a microplate reader at 37℃for 3min, 50. Mu.L of supernatant was added to each well by a row gun, and the reaction was measured at OD 420 The enzyme activity of each clone was measured at the change in absorbance within 1 min.
In the examples below, all chemical reagents are commercially available and used without further purification, except as specifically indicated. The SanPrep column type plasmid DNA small extraction kit, the SanPrep column type DNA gel recovery kit and the SanPrep column type PCR product recovery kit are all purchased from Shanghai biological engineering, 2X Specific Taq Master Mix is purchased from offshore protein, P520 high-fidelity enzyme and C115 homologous recombination kit is purchased from Norvezan, and 2,2' -azino-bis (3-ethylbenzothiazole-6-sulfonic Acid) (ABTS) is purchased from Biyunnanensis.
Example 1
More than 30 laccase genes from different sources are downloaded on NCBI, laccase LAC1 gene sequences are compared with laccase genes from different sources by utilizing analysis software ClustalX, structural domains and active centers of the sequences are analyzed, sections affecting enzyme activity and substrate specificity are found out, random bases are respectively added to specific positions of key areas of a second structural domain and a third structural domain when DNA fragments are chemically synthesized, and the synthesis of two random mutant sequences is entrusted to a biological organism. The random mutation sequence is shown in Table 1, and the laccase LAC1 gene sequence is shown in SEQ ID NO. 4.
TABLE 1 random mutant sequences
The underlined in table 1 indicates the random mutation incorporation sites.
Example 2
Primers were designed for random mutant sequences, reverse PCR primers were designed for the vector, PCR procedures for pET-32a (+) -LAC linearized expression vector were as shown in Table 2, related primers were as shown in Table 3, and PCR procedures for random mutant sequences were as shown in Table 4.
TABLE 2 PCR reaction procedure for LAC1 Gene expression vectors
TABLE 3 random mutant Gene expression library-related primers
Primer name | Primer sequence (5 '. Fwdarw.3') |
Random mutant sequence 1-F | CACTCCTTCCTCTACGACTT |
Random mutant sequence 1-R | CGCAGGCCGTCACAGTACTGGG |
Random mutant sequence 2-F | TTCGCCATCGTCTTCGCCGA |
Random mutant sequence 2-R | GCAGCTTGTCGTAGATGGGA |
pET32a-1-F | CCCAGTACTGTGACGGCCTGCG |
pET32a-1-R | GTAGAGGAAGGAGTGGCCGG |
pET32a-2-F | TCTACGACAAGCTGCCCGAG |
pET32a-2-R | GAAGACGATGGCGAAGCCGG |
TABLE 4 random mutant sequence PCR reaction procedure
After the PCR reaction procedure was completed, the pET-32a (+) -LAC1 linearized vector was electrophoretically detected with 1% agarose gel and the random mutation sequence was electrophoretically detected with 2.5% agarose gel.
Linearized vectors and random mutation sequences were recovered by using a SanPrep column gel recovery kit according to the instructions, and the concentrations and purities were determined and stored at-20 ℃.
Example 3
The construction schematic diagram of the random mutant sequence recombinant vector pET-32a (+) -LAC1 is shown in figure 1, and the method is utilizedUltra One Step Cloning Kit the two mutant sequences and the expression vector were connected in sequence, as shown in FIG. 2, and a homologous recombination reaction system was prepared according to Table 5, and the homologous recombination reaction procedure is shown in Table 6.
TABLE 5 homologous recombination reaction System
System composition | Dosage of |
Linearization carrier | 140ng |
Insertion fragment | 20ng |
2×ClonExpress Mix | 5μL |
ddH 2 O | Supplement 10 mu L |
In Table 5, the optimum cloning vector was used in an amount= [0.02×cloning vector base pair number ] ng (0.03 pmol), and the optimum insert was used in an amount= [0.04×insert base pair number ] ng (0.06 pmol).
TABLE 6 homologous recombination reaction procedure
Step (a) | Temperature (. Degree. C.) | Reaction time (min) |
1 | 50 | 15 |
In Table 6, the recombination time was prolonged to 30min, and the recombination efficiency was improved, but not more than 1h at maximum.
Example 4
Immediately after the homologous recombination reaction was completed, the ligation product was transformed into DH 5. Alpha. Competent cells as follows:
(1) 50ul E.coli DH5α for cloning was thawed on ice.
(2) 10. Mu.L of the recombinant product was added to 100. Mu.L of competent cells, and the mixture was stirred well against the walls of the flick tube and allowed to stand on ice for 30min.
(3) After heat shock in a water bath at 42 ℃ for 90sec, the mixture was immediately placed on ice and cooled for 3min.
(4) 900. Mu.L of LB liquid medium (without antibiotics) was added, and the mixture was shaken at 37℃and 220rpm for 1 hour, and the solid LB medium plate was sterilized under an ultra-clean bench by an ultraviolet lamp.
(5) The bacterial solution was centrifuged at 5000rpm for 5min, the bacterial solution was resuspended in the remaining medium and gently spread on plates containing the correct resistance.
(6) After plating, the plate is transferred to a constant temperature incubator at 37 ℃ for culturing for 10min on the front surface, and then the plate is reversely cultured until the plate is harvested every noon.
Transforming competent cells E.coli DH5 alpha, constructing a random mutant gene expression library, randomly picking a monoclonal from the obtained random mutant gene library, and sequencing and analyzing about 2-6 amino acids of each mutant. On the basis, the mixed plasmid of the random mutant gene library is extracted and transferred into E.coli BL21 (DE 3) competent cells.
Example 5
(1) mu.L of sterilized ddH was added sequentially to the PCR well plate 2 O; randomly picking single bacterial colony with good growth state by using a 10uL gun head, blowing the gun head in a hole, imprinting on a new LB flat plate containing Amp, designing and synthesizing colony PCR primer of pET-32a (+) -LAC1 random mutation sequence expression vector, and detecting whether a target fragment is correctly inserted or notEntering; the primer sequences are shown in Table 7.
(2) Plates were incubated with single colonies in an incubator at 37℃overnight in an inverted position.
(3) A residual colony PCR reaction system was added to each well of the PCR well plate in sequence according to Table 8, and a drop of paraffin oil was added dropwise to the well plate with a yellow gun head to seal the liquid surface, and the colony PCR reaction procedure was as shown in Table 9.
TABLE 7 colony PCR primer for pET-32a (+) -LAC1 random mutant sequence expression vector
Primer name | Primer sequence (5 '. Fwdarw.3') |
RD primer1 | CATCCACTGGCACGGCTTCT |
Random mutant sequence 1-R | CGCAGGCCGTCACAGTACTGGG |
Random mutant sequence 2-R | GCAGCTTGTCGTAGATGGGA |
Note that: colony PCR upstream primers of all pET-32a (+) -LAC1 random mutant sequence expression vectors are used as a universal primer RD primer1 on the vector, and downstream primers are used as downstream primers of random mutant sequences.
TABLE 8 colony PCR reaction System
System composition | Dosage of |
Stencil (Single colony DNA) | Gun head picking |
Colony PCR primer (2 mu M) | 2.5μL |
2×Taq Master Mix | 5μL |
ddH 2 O | 5 mu L (added in advance) |
TABLE 9 colony PCR reaction procedure
mu.L of colony PCR products were taken from each well and electrophoretically detected on a 2.5% agarose gel.
Sequencing and identification: the positive bands in the control electrophoresis results were compared, the corresponding monoclonal colonies were picked up on the plate, the monoclonal colonies were picked up with a 10. Mu.L tip in a tube containing 5mL of liquid LB medium, and 5. Mu.LAMP was added and incubated overnight at 37℃with a constant temperature shaker at 220 rpm. 500mL of added glycerol was aspirated in an ultra clean bench and stored at-80℃and the remaining plasmid was extracted using the SanPrep column plasmid DNA miniprep extraction kit and sent to Sangon for sequencing and identification.
Example 6
The filter paper which is not unsealed is cut into flat plates, the flat plates are sterilized under high pressure, the flat plates are placed in an ultra-clean bench for ultraviolet irradiation, colonies of the flat plates which are successfully sequenced are dipped and picked up by the filter paper, pressed on a new solid culture medium containing Amp lightly, and the flat plates are placed in a constant temperature incubator at 37 ℃ for overnight. All plasmids on the plates were gently scraped off with a gun head, inoculated into tubes containing 5mL of LB medium, and incubated overnight at 37℃on a constant temperature shaker at 220 rpm. The mixed plasmid of random mutant gene library is extracted by using SanPrep column type plasmid DNA small extraction kit, and the mixed plasmid is transferred into E.coli BL21 (DE 3) competent cells.
Example 7
The overnight plate was removed, 150. Mu.L of LB medium containing Amp was added to each well of the 96-well plate, the single clone was randomly picked with a white gun head, inoculated into the 96-well plate, sealed with a sealing film, and placed in a 37℃incubator overnight. mu.L of overnight culture broth was pipetted into another well plate containing 130. Mu.L of liquid medium to culture until OD 600 Reaching about 0.6 to 0.8; the original 96-well plate bacteria liquid is stored in a sealing way and is stored at 4 ℃. mu.L of 100. Mu.M IPTG was added to each well and induced expression at 16 ℃. The cells were collected by centrifugation at 5000rpm for 15min in 96-well plates every other day, and the medium was discarded. Referring to the one-step bacterial active protein extraction kit, 500. Mu.L of Lysozyme (1. Mu.L of DTT and 10. Mu.L of PMSF are added to each 1mL of extraction reagent) is added to each well, and the mixture is repeatedly blown with a gun head to form a uniform suspension, and the uniform suspension is placed on a constant temperature shaking table and is oscillated at 220rpm for about 30min at room temperature. Centrifuge at 10000rpm for 15min at 4℃and collect the supernatant. 50 μ LpH 4.0.0 disodium hydrogen phosphate-citrate buffer was added to each well of the new 96-well plate, incubated in a microplate reader at 37℃for 3min, 50 μl of soluble supernatant was added to each well using a row gun, and the change in absorbance at OD420 was measured within 1 min. And shaking bacteria and re-screening by using a 5mL test tube.
Example 8
The sequencing result is analyzed by using a bioinformatics method, a laboratory self-built script is used for converting the sequencing result FASTA file into a FASTQ file, BWA samse is used for comparing with an original sequence, and finally an IGV is used for visualization, and then a sequence meeting the requirement is manually selected. IGV visualization is shown in fig. 3, 4.
Example 9
After a mutation library is obtained by using a homologous recombination method, 5 strains with improved enzyme activity are obtained by adopting a 96-well plate high-throughput screening method, and a strain with 2.3 times of the wild type enzyme activity is finally obtained by shaking and rescreening, and is named as LAC123. Sequencing shows that the strain LAC123 has 5 bases mutated compared with the wild type, and the base mutation site is: the base at position 1521 is synonymous mutation GAA-GAG, the base mutation GCC-GGC at position 1493, the base mutation AUC-CUC at position 1483, the base mutation AAC-CAC at position 1477, the base mutation GTC-GGC at position 1475, and the corresponding amino acid mutation sites are: V490G, N491H, I493L and a496G, which are located in the surface loop region of laccase globular three-dimensional structure, namely: valine at position 490 is mutated to glycine, asparagine at position 491 is mutated to histidine, isoleucine at position 493 is mutated to leucine, alanine at position 496 is mutated to glycine, and the amino acid sequence of LAC123 is as shown in SEQ ID NO:3, and LAC23 and LAC1 sequence pairs such as shown in FIG. 5.
And analyzing the three-dimensional structure of laccase by utilizing SWISS-MODEL molecular simulation software homologous modeling and downloading a PDB file. The mutation sites were labeled with the Pymol software and a three-dimensional structural model of laccase was obtained based on predicted structural information, as shown in fig. 6.
These results preliminarily indicate that amino acid mutants can be screened to improve enzyme activity by constructing random mutation libraries by the experimental technique.
The above-described embodiments are only preferred embodiments of the present invention, and are not intended to be limiting in any way and in nature, and it should be noted that several modifications and additions may be made to those skilled in the art without departing from the invention, which modifications and additions are also intended to be construed as within the scope of the invention.
Sequence listing
<110> university of east China
<120> method for modifying laccase by specific segment random mutation method and laccase strain LAC123
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 92
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 1
cactccttcc tctacgactt ccacgtcccc gaccaggccg gcacctnctg gnatcactcc 60
cacntcngcn cccagtactg tgacggcctg cg 92
<210> 2
<211> 97
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 2
ttcgccatcg tcttcgccga ggacgncnac gacntcaagt ncgncaaccc cgtccccccc 60
agctgggagg anctttgtcc catctacgac aagctgc 97
<210> 3
<211> 518
<212> PRT
<213> Artificial sequence (LAC 123)
<400> 3
Met Gly Ser Gly Leu Phe Ser Leu Phe Val Ala Ile Ala Ala Ile Ser
1 5 10 15
Gly Ser Leu Ala Ala Ile Gly Pro Lys Ala Asp Leu Val Ile Ser Asp
20 25 30
Ala Val Val Asn Pro Asp Gly Thr Pro Arg Ala Ala Val Val Val Asn
35 40 45
Gly Asp Phe Pro Gly Pro Leu Ile Ser Gly Lys Lys Gly Asp His Phe
50 55 60
Gln Leu Asn Val Ile Asn Lys Leu Thr Asn His Thr Met Leu Lys Thr
65 70 75 80
Thr Ser Ile His Trp His Gly Phe Phe Gln Glu His Thr Asn Trp Ala
85 90 95
Asp Gly Pro Ala Phe Val Asn Gln Cys Pro Ile Ala Ser Gly His Ser
100 105 110
Phe Leu Tyr Asp Phe His Val Pro Asp Gln Ala Gly Thr Tyr Trp Tyr
115 120 125
His Ser His Leu Ser Thr Gln Tyr Cys Asp Gly Leu Arg Gly Pro Leu
130 135 140
Val Val Tyr Asp Pro His Asp Pro Gln Ala His Leu Tyr Asp Val Asp
145 150 155 160
Asn Asp Asp Thr Val Ile Thr Leu Ala Asp Trp Tyr His Val Ala Ala
165 170 175
Lys Leu Gly Pro Gln Phe Pro Arg Gly Ala Asn Ser Thr Leu Ile Asn
180 185 190
Gly Leu Gly Arg Ala Ala Thr Asp Ser Thr Ser Asp Leu Thr Val Ile
195 200 205
Thr Val Glu His Gly Lys Arg Tyr Arg Phe Arg Leu Val Ser Ile Ser
210 215 220
Cys Asp Pro Asn His Thr Phe Ser Ile Asp Gly His Asn Met Thr Ile
225 230 235 240
Ile Glu Val Asp Gly Val Asn Ser Lys Pro Leu Thr Val Asp Ser Ile
245 250 255
Gln Ile Phe Ala Ala Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Gln
260 265 270
Pro Val Asp Asn Tyr Trp Ile Arg Ala Asn Pro Ser Gly Gly Thr Leu
275 280 285
Gly Phe Glu Gly Gly Ile Asn Ser Ala Ile Leu Arg Tyr Lys Gly Ala
290 295 300
Pro Asp Ala Glu Pro Thr Asn Thr Thr Ala Pro Thr Ser Val Ile Pro
305 310 315 320
Leu Val Glu Thr Asn Leu His Pro Leu Lys Pro Met Gln Val Pro Gly
325 330 335
Arg Ser Gly Val Gly Asn Val Asp Tyr Ala Lys Thr Leu Asn Phe Asn
340 345 350
Phe Asn Gly Thr Asn Phe Phe Ile Asn Asn Ala Thr Phe Thr Pro Pro
355 360 365
Thr Val Pro Val Leu Leu Gln Ile Leu Ser Gly Ala His Asn Ala Gln
370 375 380
Asp Leu Leu Pro Ala Gly Ser Val Tyr Thr Leu Pro Pro His Ser Ala
385 390 395 400
Ile Glu Ile Thr Met Pro Ala Thr Thr Met Ala Pro Gly Ser Pro His
405 410 415
Pro Phe His Leu His Gly His Val Phe Ala Val Val Arg Ser Ala Gly
420 425 430
Ser Ser Glu Tyr Asn Tyr His Asp Pro Ile Phe Arg Asp Val Val Ser
435 440 445
Thr Gly Gln Pro Gly Asp Ser Val Thr Ile Arg Phe Met Thr Asp Asn
450 455 460
Pro Gly Pro Trp Phe Leu His Cys His Ile Asp Phe His Leu Glu Ala
465 470 475 480
Gly Phe Ala Ile Val Phe Ala Glu Asp Gly His Asp Leu Lys Tyr Gly
485 490 495
Asn Pro Val Pro Pro Ser Trp Glu Glu Leu Cys Pro Ile Tyr Asp Lys
500 505 510
Leu Pro Glu Ser Asp His
515
Claims (1)
1. The laccase is characterized in that the amino acid sequence of the laccase is shown as SEQ ID NO. 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210194874.XA CN114703212B (en) | 2022-03-01 | 2022-03-01 | Method for modifying laccase by using specific segment random mutation method and laccase strain LAC123 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210194874.XA CN114703212B (en) | 2022-03-01 | 2022-03-01 | Method for modifying laccase by using specific segment random mutation method and laccase strain LAC123 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114703212A CN114703212A (en) | 2022-07-05 |
CN114703212B true CN114703212B (en) | 2024-03-29 |
Family
ID=82166849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210194874.XA Active CN114703212B (en) | 2022-03-01 | 2022-03-01 | Method for modifying laccase by using specific segment random mutation method and laccase strain LAC123 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114703212B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027197A1 (en) * | 1996-12-19 | 1998-06-25 | Novo Nordisk A/S | Myceliophthora and scytalidium laccase variants having improved stability |
CN102876623A (en) * | 2012-09-29 | 2013-01-16 | 南京师范大学 | Re-engineering mediated site-directed mutagenesis method |
JP2014003970A (en) * | 2012-05-30 | 2014-01-16 | Aisin Seiki Co Ltd | Highly active mutant of protein having laccase activity, nucleic acid molecule encoding the same and use thereof |
CN108486139A (en) * | 2018-02-27 | 2018-09-04 | 温州医科大学 | A kind of site-directed point mutation method and its application based on seamless clone technology |
CN112921043A (en) * | 2021-03-16 | 2021-06-08 | 安徽大学 | Mutant nucleic acid, expression vector, laccase mutant with high specific activity and preparation method thereof |
CN113930401A (en) * | 2021-12-21 | 2022-01-14 | 中国农业科学院北京畜牧兽医研究所 | Method for improving laccase catalytic activity, mutant Lcc9-M1, gene and application |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2236611A1 (en) * | 2000-04-28 | 2010-10-06 | Novozymes A/S | Lipolytic enzyme variant |
PL2756076T3 (en) * | 2011-09-15 | 2017-10-31 | Metgen Oy | Enzyme variants with improved properties |
-
2022
- 2022-03-01 CN CN202210194874.XA patent/CN114703212B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027197A1 (en) * | 1996-12-19 | 1998-06-25 | Novo Nordisk A/S | Myceliophthora and scytalidium laccase variants having improved stability |
JP2014003970A (en) * | 2012-05-30 | 2014-01-16 | Aisin Seiki Co Ltd | Highly active mutant of protein having laccase activity, nucleic acid molecule encoding the same and use thereof |
CN102876623A (en) * | 2012-09-29 | 2013-01-16 | 南京师范大学 | Re-engineering mediated site-directed mutagenesis method |
CN108486139A (en) * | 2018-02-27 | 2018-09-04 | 温州医科大学 | A kind of site-directed point mutation method and its application based on seamless clone technology |
CN112921043A (en) * | 2021-03-16 | 2021-06-08 | 安徽大学 | Mutant nucleic acid, expression vector, laccase mutant with high specific activity and preparation method thereof |
CN113930401A (en) * | 2021-12-21 | 2022-01-14 | 中国农业科学院北京畜牧兽医研究所 | Method for improving laccase catalytic activity, mutant Lcc9-M1, gene and application |
Also Published As
Publication number | Publication date |
---|---|
CN114703212A (en) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108795916B (en) | Lysine decarboxylase mutant, coding gene thereof, expression and application thereof | |
CN113073089B (en) | Novel method for improving enzyme activity of NMN biosynthetic enzyme Nampt | |
CN112391372B (en) | Glutamic acid decarboxylase mutant, genetically engineered bacterium and application thereof | |
CN109971734B (en) | PH-insensitive high-temperature-tolerant HSL family lipid hydrolase and application thereof | |
CN112359032B (en) | Mutant esterase and application thereof, recombinant vector and preparation method and application thereof, recombinant engineering bacteria and application thereof | |
CN114317507A (en) | Nitrile hydratase mutant and application thereof | |
CN114703212B (en) | Method for modifying laccase by using specific segment random mutation method and laccase strain LAC123 | |
CN111139229B (en) | Novel GDSL family lipid hydrolase EII-2 and encoding gene and application thereof | |
CN113249349B (en) | Mutant alcohol dehydrogenase, recombinant vector, preparation method and application thereof | |
CN112301014B (en) | Esterase mutant with improved thermal stability and application thereof | |
CN115717137A (en) | Lysyl-specific endonuclease mutant and preparation method and application thereof | |
CN113308453B (en) | Amidohydrolase SaAH, and coding gene and application thereof | |
US11807883B2 (en) | Polypeptide tag, highly soluble recombinant nitrilase and application thereof in synthesis of pharmaceutical chemicals | |
CN115948363A (en) | Tn5 transposase mutant and preparation method and application thereof | |
CN111172143B (en) | D-xylonic acid dehydratase and application thereof | |
CN114214308A (en) | Nitrilase mutant with activity improved through semi-rational modification | |
KR20000060418A (en) | Method for Preparing Enzyme Variants Including High Throughput Screening | |
CN114250206B (en) | Methyltransferase mutant, recombinant vector, recombinant engineering bacterium and application thereof | |
CN114525266B (en) | Phospholipase D mutant from Antarctic bacteria and application thereof | |
KR0184755B1 (en) | Thermostable tyrosine phenol-lyase and the preparation process of l-dopa using it | |
CN114196658B (en) | Nitrilase mutant and application thereof in catalytic synthesis of 2-chloronicotinic acid | |
RU2313575C1 (en) | PLASMID pNAN5 DETERMINING SYNTHESIS OF L-ASPARAGINASE EcA2, BACILLUS CEREUS 1576-pNAN5 STRAIN - INDUSTRIAL STRAIN-PRODUCER OF RECOMBINANT L-ASPARAGINASE EcA2 AND METHOD FOR ITS PREPARING | |
JP4117823B2 (en) | Method for producing thermostable hydrogenase | |
CN114277013A (en) | NAD kinase mutant and application thereof | |
CN116769757A (en) | Aminopeptidase, mutant, coding gene and application of aminopeptidase and mutant in L-carnosine synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |